Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients

• Asıl Yazarlar: Thomas Monfeuga (Yazar), Jenny Norlin (Yazar), Anne Bugge (Yazar), Elisabeth D. Gaalsgaard (Yazar), Cesar A. Prada-Medina (Yazar), Markus Latta (Yazar), Sanne S. Veidal (Yazar), Pia S. Petersen (Yazar), Michael Feigh (Yazar), Dorte Holst (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Elsevier, 2024-01-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Objective: The metabolic benefits of GLP-1 receptor (GLP-1R) agonists on glycemic and weight control are well established as therapy for type 2 diabetes and obesity. Glucagon's ability to increase energy expenditure is well described, and the combination of these mechanisms-of-actions has the p...